Drug Discovery and Development of miRNA-Based Nucleotide Drugs for Gastrointestinal Cancer.
Biomedicines
; 11(8)2023 Aug 09.
Article
en En
| MEDLINE
| ID: mdl-37626731
Short non-coding RNAs, miRNAs, play roles in the control of cell growth and differentiation in cancer. Reportedly, the introduction of miRNAs could reduce the biologically malignant behavior of cancer cells, suggesting a possible use as therapeutic reagents. Given that the forced expression of several miRNAs, including miR-302, results in the cellular reprograming of human and mouse cells, which is similar to the effects of the transcription factors Oct4, Sox2, Klf4, and c-Myc, this suggests that the selective introduction of several miRNAs will be able to achieve anti-cancer effects at the epigenetic and metabolic levels. In this review article, we bring together the recent advances made in studies of microRNA-based therapeutic approaches to therapy-resistant cancers, especially in gastrointestinal organs.
Texto completo:
1
Bases de datos:
MEDLINE
Idioma:
En
Revista:
Biomedicines
Año:
2023
Tipo del documento:
Article
País de afiliación:
Japón